INTRODUCTION
When metformin and lifestyle changes become insufficient in treating type 2 diabetes mellitus (T2DM), advancing treatment with traditional therapies (sulfonylureas [SUs] , thiazolidinediones [TZDs] , and insulin) can be complicated by weight gain and hypoglycemia [1] . In clinical trials, adding incretin-based therapies to existing oral therapy has been shown to improve glycemic control without weight gain and with low hypoglycemia incidence (especially when used without SUs) [2] [3] [4] [5] [6] . Head-to-head studies of up to 12 months' duration suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) have greater glycemic efficacy and result in significantly more weight loss compared with the dipeptidyl peptidase-4 inhibitor (DPP-4i) sitagliptin [7] [8] [9] [10] . Furthermore, patientreported data suggest a greater improvement in treatment satisfaction with liraglutide 1.8 mg versus sitagliptin; treatment satisfaction data were similar for liraglutide 1.2 mg versus sitagliptin [11] .
The National Institute of Health and Clinical Excellence (NICE) recommendations for incretin-based therapies reflect their key benefits, endorsing use (in combination with one or two oral therapies) when hypoglycemia and/or weight gain are a particular concern [12] [13] [14] . In general, DPP-4is recommended earlier in the treatment pathway, with less stringent treatment continuation criteria compared with GLP-1RAs. While incretinbased therapies have been compared in clinical trials [7-10, 15, 16] , Data comparing their relative efficacy in clinical practice remains limited, particularly when prescribed according to clinical guidelines.
With these issues in mind, using primary care data, a retrospective chart audit was conducted to compare the clinical and costeffectiveness of liraglutide, exenatide twice daily (b.i.d.), and DPP-4is when initiated according to current NICE recommendations. Once-weekly exenatide was not included as it was unavailable for routine use at the time of this study. As NICE also advocates patient involvement in therapy choice and treatment goals [17] , the audit was complemented by a prospective patient preference survey in patients considered appropriate for treatment intensification with incretin-based therapy. The survey's aim was to compare preferences for GLP-1RAs with DPP-4is. Based on clinical trial data, it was hypothesized that liraglutide would provide greater glycated hemoglobin (HbA 1c ) efficacy compared with DPP-4is and exenatide. As GLP-1RA use can result in weight loss, we also hypothesized that patients with a greater baseline body mass index (BMI) would prefer a drug with a GLP-1RA profile. liraglutide, data from that study were used for the patient preference questionnaire for route of administration, efficacy, side effects, and treatment satisfaction [7, 8, 11] . Informed consent was obtained and patients were asked which drug they would prefer to be prescribed in addition to their current medication if their blood sugar levels were too high. Subsequent responses were anonymized and results collated.
PATIENTS AND METHODS
As in a previous patient preference survey [21] , after patients reported their preference, they were asked to rank the importance of the following reasons for their decision:
administration method (oral or injection); blood glucose-lowering effect; side-effects (nausea, vomiting, and diarrhea); and other effects (weight loss and blood pressure decrease). Continuous variables were compared using a t test, categorical variables using a v 2 test, and overall patient preference was assessed by logistic regression, controlling for all demographic and patient characteristic variables. All analyses and statistical calculations were performed using SAS and Minitab, as for the retrospective survey.
RESULTS

Retrospective Survey
Baseline Characteristics
In total, 1,114 patients had detailed baseline and follow-up data and were included in the retrospective audit: 256 received liraglutide At baseline, patients initiated on liraglutide or exenatide therapy had significantly higher mean baseline HbA 1c , durations of diabetes, and Side effects This medication has a low risk of hypoglycemia (blood sugar levels going much too low) unless you are also taking a sulfonylurea (for example gliclazide), where there might be a higher risk of you experiencing hypoglycemia This medication has a low risk of hypoglycemia (blood sugar levels going much too low) unless you are also taking a sulfonylurea (for example gliclazide), where there might be a higher risk of you experiencing hypoglycemia About 10-20% of patients who take this medication may have feelings of sickness and about 5-7% may actually be sick About 8-15% of patients taking this medication may suffer from diarrhea. These side-effects normally go away after about 1 month (individual results may vary)
Other effects This medication has no effects on weight or blood pressure, and people who have been given this medication say that they are now more satisfied with their treatment
This medication may lead to a weight loss of about 7.5 lb, as well as a small reduction in blood pressure. People who have been given this medication say that they are now more satisfied with their treatment
Patients were shown the two medication profiles and given the following instructions: ' 'At the moment, your blood sugar levels are still too high and we will need to
give you an additional treatment to take with your current medication to help lower your blood sugar levels. Written below are the descriptions of two different medicines that are often given to people in your situation, with type 2 diabetes, to help lower their blood sugar levels (note: neither one is insulin). Based on the descriptions below, please tick which one you would prefer to take in addition to your current treatments. The proportions of patients achieving the NICE 6-month treatment continuation criteria for GLP-1RAs with liraglutide 1.2 mg and exenatide were 32% and 24%, respectively.
For DPP-4is, 61% of patients achieved the less stringent criteria at 6 months. The composite endpoint of C1% HbA 1c reduction with any weight loss was achieved by 60%, 48%, and 14% of patients treated with liraglutide AEs were more common in patients taking exenatide and liraglutide (39% and 29%, respectively) than DPP-4is (9.6%). The most commonly recorded AEs with liraglutide (26.5%) and exenatide (33.1%) were gastrointestinal (diarrhea, nausea, vomiting, abdominal pain, constipation, anorexia). The most commonly reported side effects with DPP-4is were diarrhea (3.9%), headache (2.1%), and nausea (1.7%). No major hypoglycemia was recorded; symptomatic hypoglycemia was recorded in 0.8%, 0.9%, and 0.8% of people taking liraglutide, exenatide, or a DPP-4i, respectively.
Cost-Effectiveness Analyses
Based on the end-of-audit observations, the calculated life-years gained per patient, compared with baseline, were 0.12, 0.08, and 0.07 for liraglutide, exenatide, and DPP-4i, respectively. The observed costs per QALY versus baseline for patients prescribed liraglutide, exenatide, or DPP-4i were £16,505, £16,648, and £20,661, respectively.
Prospective Survey of Patient Preference
A total of 188 patients completed the survey, with a mean (±SD) age of 63.9 years (±5.9), body weight 97.5 kg (±8.6), BMI 36.7 kg/m 2 (±5.9), and HbA 1c 74 mmol/mol (8.9%) (±1.1). Based on medication profiles provided, significantly more patients (62.5% vs. 37.5%) reported a preference for the drug with the GLP-1RA profile compared with the DPP-4i profile (P\0.05). The demographics of patients choosing each drug are shown in Table 4 . upon which the criteria are based [2, 22] . Achieving a 6-month 3% body weight loss may have been unrealistic for severely obese Despite widespread use of concomitant SU therapy, symptomatic hypoglycemia was reported by few patients (\1%). This may reflect underreporting by both patients and healthcare professionals and may also be related to the high baseline levels of glucose control. Gastrointestinal side effects were the most frequently reported AE in exenatide-(33.1%) and liraglutide-treated (26.5%) patients, in line with rates from clinical trials [22, 26] . However, therapy discontinuation due to gastrointestinal side effects was greater than seen in clinical trials [6] [7] [8] 15] , possibly reflecting the impact of routine practice, as opposed to the clinical trial setting, which often includes highly motivated patients who undergo more monitoring than patients in routine clinical practice.
The health economic observations represent the cost-effectiveness profile of liraglutide, exenatide, and DPP-4is as prescribed in routine clinical practice, and thus may be more noteworthy than similar data derived from trials.
However, as this analysis was limited to withintreatment group assessments compared with baseline, and as patients who were prescribed GLP-1RAs were markedly phenotypically different from those prescribed DPP-4is, it is impossible to directly compare the costeffectiveness profiles of the different therapies.
The majority of patients surveyed preferred the GLP-1RA profile (62.5%) over the DPP-4i profile (37.5%); however, the phenotypic profile of the survey population may have been a source of potential bias with respect to the observed results. These data are at variance with a previous study [21] , and may partly reflect the to weight loss, may outweigh barriers presented by an injectable mode of administration. This is supported by treatment satisfaction data from the liraglutide versus sitagliptin phase 3 study [11] . For patients already close to their individual glycemic target, and for whom weight is not a particular concern, the ease of adding an orally administered DPP-4i to existing therapy may, however, be preferable.
While real-world observations such as these provide useful insight into the utility of different 
